The Lancet HIV · 2022 · 24 citations · 12 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPediatric Clinical PharmacologyTuberculosis ControlAntiretroviral TherapyPediatric Clinical TrialsPediatric Drug DosingPediatric PharmacokineticsPediatric TuberculosisTuberculosis In ChildrenArea Under The Plasma Concentration-time CurveDaily DosingGeometric Mean RatioPediatric Antiretroviral TherapyPediatric Tuberculosis PharmacokineticsPharmacokinetic Area Under The CurvePharmacokinetic ParametersRifampicin Therapy
BACKGROUND: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. METHODS: on the first substudy day. All children within ODYSSEY with HIV-associated TB who received rifampicin and twice-daily dolutegravir were included in the safety analysis. We described adverse events reported from starting twice-daily dolutegravir to 30 days after returning to once-daily dolutegravir. This trial is registered with ClinicalTrials.gov (NCT02259127), EudraCT (2014-002632-14), and the ISRCTN registry (ISRCTN91737921). FINDINGS: was 5·1 mg/L (coefficient of variation 71%). During a median follow-up of 31 weeks (IQR 30-40), 15 grade 3 or higher adverse events occurred among 11 (30%) of 37 children, ten serious adverse events occurred among eight (22%) children, including two deaths (one tuberculosis-related death, one death due to traumatic injury); no adverse events, including deaths, were considered related to dolutegravir. INTERPRETATION: Twice-daily dolutegravir was shown to be safe and sufficient to overcome the rifampicin enzyme-inducing effect in children, and could provide a practical ART option for children with HIV-associated TB. FUNDING: Penta Foundation, ViiV Healthcare, UK Medical Research Council.
12
Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 298 citations
Kelly E. Dooley, Patrick Sayre, Julie Borland et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 192 citations